Dr. Lalefar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
747 52nd St
Oakland, CA 94609Phone+1 510-428-3885Fax+1 510-597-7199
Education & Training
- Children's Hospital-OaklandFellowship, Pediatric Hematology/Oncology, 2012 - 2015
- University of California (San Francisco)/FresnoResidency, Pediatrics, 2008 - 2011
- University of California, Davis, School of MedicineClass of 2008
Certifications & Licensure
- CA State Medical License 2010 - 2025
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202) Start of enrollment: 2023 Jan 25
Roles: Contact
Publications & Presentations
PubMed
- 13 citationsKIR-favorable TCR-αβ/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial.Michael A Pulsipher, Kwang W Ahn, Nancy J Bunin, Nahal Lalefar, Eric Anderson
Blood. 2022-12-15 - 107 citationsPhase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.Benjamin Watkins, Muna Qayed, Courtney McCracken, Brandi Bratrude, Kayla Betz
Journal of Clinical Oncology. 2021-01-15 - 3 citationsProspective Validation and Refinement of a Population Pharmacokinetic Model of Fludarabine in Children and Young Adults Undergoing Hematopoietic Cell Transplantation.Jordan T Brooks, Belen P Solans, Ying Lu, Sandhya Kharbanda, Christopher C Dvorak
Pharmaceutics. 2022-11-15
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: